Arrowhead Pharmaceuticals, Inc. (ARWR) continued its upward trend with the stock climbing 5.47% or $0.11 to close the day at $2.12 on light trading volume of 1.7M shares, compared to its three month average trading volume of 1.96M. The Pasadena California 91101 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -46.19%, compared to the industry which has advanced 0.95% over the same period. With RSI of 63.15, the stock should still continue to rise and get closer to its one year target estimate of $1.8, making it a hold for now.
Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Penn National Gaming, Inc. (PENN) climbed 4.5% during last trading as the stock added $0.62 to finish the day at $14.41 with about 1.7M shares changing hands, compared to its three month average trading volume of 1.07M. The $1.23B market cap company, which fluctuated between $13.79 and $14.56 during the day, currently situated 20.79% above its 52 week low of $11.93 and -17.18% away from its one year high of $17.4. The RSI of 57.93 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.
Penn National Gaming, Inc. owns and manages gaming and racing facilities, and operates video gaming terminals with a focus on slot machine entertainment. The company operates through East/Midwest, West, and Southern Plains segments. As of December 31, 2015, it operated 27 facilities in 17 jurisdictions, including Florida, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Mississippi, Missouri, Nevada, New Jersey, New Mexico, Ohio, Pennsylvania, Texas, West Virginia, and Ontario. The company was formerly known as PNRC Corp. and changed its name to Penn National Gaming, Inc. in 1994. Penn National Gaming, Inc. was founded in 1972 and is based in Wyomissing, Pennsylvania.
Impax Laboratories, Inc. (IPXL) saw its value increase by 4.96% as the stock gained $0.7 to finish the day at a closing price of $14.8. The stock was higher in trading and has fluctuated between $11.65-$37.2 per share for the past year. The shares, which traded within a range of $14 to $14.9 during the day, are up by 2.07% in the past three months and down by -35.29% over the past six months. It is currently trading 14.02% above its 20 day moving average and 12.66% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $18.47 a share over the next twelve months. The current relative strength index (RSI) reading is 69.11. The technical indicator lead us to believe there will be no major movement any time soon, hold.
Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Impax Generics and Impax Specialty Pharma. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, large retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance and collaboration agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance, collaboration, and supply agreements. The Impax Specialty Pharma segment focuses on the development and promotion through its specialty sales force of proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinson’s disease, and postherpetic neuralgia. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals Curacao N.V to develop, manufacture, and distribute controlled release generic pharmaceutical products. The company was founded in 1993 and is headquartered in Hayward, California.